Information CTR

Clinical trial application (CTR): from start to finish

The timeline below describes a clinical trial application under the EU Clinical Trial Regulation (CTR) from start to finish. See for a full overview the website of the CCMO.

National or multinational: general information

The CTR is applicable to national and multinational clinical trials.


For a national clinical trial, the reporting Member State (rMS) is the MS to which the clinical trial application is submitted.


For multinational clinical trials there will be a coordinated and consolidated assessment  by the Member States where the trial is intended to be carried out.  For multinational trials, the sponsor proposes a rMS but it is up to the concerned Member State (cMS) to express their willingness to become rMS during the first 3 days of the application.

Research file: full, staggered or mixed applications

The sponsor is allowed to submit a full initial application (part I and part II at the same time), a staggered initial application (first part I followed by part II) or a mixed initial application (full, staggered or mixed applications).

Mixed initial applications in a multinational clinical trial: The sponsor can submit a whole application (Part I and II) to some Member States concerned (on the basis of article 5 CTR) and at the same time an application limited to Part I only (on the basis of article 11 CTR) to other Member States concerned.

Full or staggered application in the Netherlands

These committees will be responsible for the Part I  and Part II assessment including ethical review. This means one integrated assessment by one committee within the timelines set. It is therefore advised to submit Part I and Part II in parallel.

Clinical Trials Information System (CTIS)

A main characteristic of the CTR is an application procedure via a single entry point- an EU portal and database (CTIS), for all clinical trials to be conducted in the EU/EEA.

Research dossier Part I and Part II

See for more information about the Research dossier Part I and Part II the CCMO website.


The sponsor proposes a Member State to act as reporting Member State (rMS).


The CTR foresees strict and in some cases fatal deadlines. The clock starts running the day after the application is submitted and follows the Central European Time (CET). The Netherlands uses CET.

Each phase, from validation, assessment and decision, has its own maximum deadline for MSs and sponsors. The deadlines are set in calendar days and follow the rules as set in Regulation 1182/71. This means that the due date can never fall on a weekend day or an official holiday. Neither can a time period be shorter than two consecutive working days. For multinational trials, official holidays of rMS and/or MSc are taken into account depending on the hard task of rMS/MSc . The deadlines are visible in CTIS.

Christmas clock stop

There is an informally agreed Christmas clock stop between 23 December and 7 January for all clinical trials, i.e national and multinational. The sponsor must indicate any objections against this clockstop to the rMS in time. There are no other clock stops within the procedures.


The following submissions are for notifications:

Modifications (amendments)